Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:53 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 889–912 of 1,850 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Deformity; Skin Clear all
Recruiting Phase 3 Interventional

The Cancer of the Pancreas Screening-5 CAPS5)Study

NCT02000089
View directory record Official record
Conditions
Pancreas Cancer, Peutz-Jeghers Syndrome (PJS), Gene Mutation, Germline Mutation Carrier, Lynch Syndrome
Interventions
Secretin, MRI, Tumor marker gene test with CA19-9
Drug · Diagnostic Test · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
9,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2029
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 27, 2026, 4:53 AM EDT
Recruiting Not applicable Interventional

Complex Aortic Aneurysm Repair Using Physician Modified Endografts and Custom Made Devices

NCT02050113
View directory record Official record
Conditions
Complex Aortic Aneurysms, Thoracoabdominal Aneurysms, Pararenal Aneurysms, Juxtarenal Aneurysms, Marfan Syndrome, Ehlers-Danlos Syndrome, Loeys-Dietz Syndrome, Aortic Arch Aneurysm
Interventions
Custom Made Fenestrated or Branched Stent Graft
Device
Lead sponsor
Andres Schanzer
Other
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2030
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 22, 2025 · Synced Oct 27, 2026, 4:53 AM EDT
Completed Early Phase 1 Interventional

Pilot Study Evaluating Sulforaphane in Atypical Nevi-Precursor Lesions

NCT01568996
View directory record Official record
Conditions
Atypical Nevi, Melanoma
Interventions
broccoli sprout extract - sulforaphane (BSE-SFN)
Drug
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2018 · Synced Oct 27, 2026, 4:53 AM EDT
Not listed No phase listed Observational

Study of Systemic Amyloidosis Presentation and Prognosis

NCT00004374
View directory record Official record
Conditions
Amyloidosis
Interventions
Not listed
Lead sponsor
National Center for Research Resources (NCRR)
NIH
Eligibility
0 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1979
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 4:53 AM EDT
Completed Not applicable Interventional

Bleach vs. Bubbles: Assessing the Impact of the Bathroom Environment on Eczema

NCT03619161
View directory record Official record
Conditions
Eczema, Atopic Dermatitis, Atopic Dermatitis and Related Conditions
Interventions
Bubbles, Bleach and Bubbles
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
6 Months to 17 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2021 · Synced Oct 27, 2026, 4:53 AM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Evaluate the Safety and Efficacy of AGE Serum in Post-menopausal Patients on Hormone Replacement Therapy Taking Glucagon-like Peptide-1 Agonist

NCT07558603
View directory record Official record
Conditions
Laxity; Skin
Interventions
On GLP1 plus HRT, On GLP1 Only
Drug
Lead sponsor
Goldman, Butterwick, Fitzpatrick and Groff
Other
Eligibility
45 Years to 65 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 27, 2026, 4:53 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

How Shoes With Rocker Soles Affect Walking

NCT00006438
View directory record Official record
Conditions
Diabetic Feet
Interventions
Shoes with Rocker Soles
Device
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
40 Years to 60 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 1999
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 27, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

NCT04232085
View directory record Official record
Conditions
Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure, Short Telomere Length, Fanconi Anemia, Non Fanconi DNA-DSB Repair Disorder, Hoyeraal-Hreidarsson Syndrome, Dyskeratosis Congenita, Telomere Biology Disorder, Short Telomere Syndrome
Interventions
Alemtuzumab, Fludarabine, Melphalan, Low Dose Total Body Irradiation, Cyclophosphamide, Tacrolimus, Mycophenolate Mofetil
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
4 Months to 50 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 27, 2026, 4:53 AM EDT
Recruiting No phase listed Observational

Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)

NCT06669949
View directory record Official record
Conditions
Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
Interventions
no intervention
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Oct 27, 2026, 4:53 AM EDT
Terminated Phase 3 Interventional Results available

A Study of Baricitinib (LY3009104) in Participants With Moderate to Severe Atopic Dermatitis

NCT03559270
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Baricitinib
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
374 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
53
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encinitas, California + 44 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 27, 2026, 4:53 AM EDT
Terminated Not applicable Interventional Results available

Personalized Interactive Laser Therapy of Port Wine Stain

NCT00782483
View directory record Official record
Conditions
Port Wine Stain
Interventions
ThermoVision A20M Infrared Camera, ScleroPLUS, 3D Digital Camera
Device
Lead sponsor
University of Arkansas
Other
Eligibility
3 Months to 17 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 27, 2026, 4:53 AM EDT
Completed Phase 3 Interventional

Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis

NCT03422822
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Abrocitinib 100 mg, Abrocitinib 200 mg, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
3,166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
156
States / cities
Birmingham, Alabama • Anaheim, California • Encinitas, California + 101 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2026 · Synced Oct 27, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors

NCT04252339
View directory record Official record
Conditions
Solid Tumor, Unspecified, Adult
Interventions
RLY-1971
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Lake Mary, Florida • Sarasota, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Oct 27, 2026, 4:53 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Skin Microbial Ecology in Atopic Dermatitis

NCT04170244
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis, Healthy
Interventions
AD subject visit sampling procedures, PS subject visit sampling procedures, Healthy control visit sampling procedures
Other
Lead sponsor
University of Rochester
Other
Eligibility
13 Years and older
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2027
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 27, 2026, 4:53 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Study of Long Term Safety and Clinical Outcomes of Idursulfase IT and Elaprase Treatment in Pediatric Participants Who Have Completed Study HGT-HIT-094

NCT02412787
View directory record Official record
Conditions
Hunter Syndrome
Interventions
Idursulfase-IT, Elaprase
Drug
Lead sponsor
Shire
Industry
Eligibility
Up to 18 Years · Male only
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
3
States / cities
Oakland, California • Chicago, Illinois • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 19, 2025 · Synced Oct 27, 2026, 4:53 AM EDT
Terminated Early Phase 1 Interventional

COVID-19 Vaccination in Rheumatic Disease Patients

NCT04839315
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Sjogren's Syndrome, Inflammatory Myositis, Psoriatic Arthritis, Gout, Ankylosing Spondylitis, Arthritis of Multiple Sites Associated With Inflammatory Bowel Disease (Diagnosis), Osteoarthritis
Interventions
mRNA COVD19 vaccine
Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 3, 2022 · Synced Oct 27, 2026, 4:53 AM EDT
Completed Not applicable Interventional Results available

Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant

NCT00293384
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Nausea and Vomiting, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
Aprepitant, Cyclophosphamide, Dexamethasone, Granisetron hydrochloride
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 120 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 27, 2026, 4:53 AM EDT
Recruiting Phase 2 Interventional

Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD

NCT07441395
View directory record Official record
Conditions
Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema, Eczema, Atopic
Interventions
Soquelitinib, Placebo
Drug
Lead sponsor
Corvus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
South San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2026 · Synced Oct 27, 2026, 4:53 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study To Evaluate ASN002 In Subjects With Atopic Dermatitis

NCT03139981
View directory record Official record
Conditions
Dermatitis, Atopic, Dermatitis Eczema, Dermatitis, Eczematous
Interventions
ASN002, Placebo Oral Tablet
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
9
States / cities
Fremont, California • Los Angeles, California • San Diego, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 10, 2023 · Synced Oct 27, 2026, 4:53 AM EDT
Recruiting No phase listed Observational

Evaluating the Genetics and Immunology of Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Cervical Adenitis (PFAPA) Syndrome and Other Tonsil Disorders

NCT05656365
View directory record Official record
Conditions
Periodic Fever, Aphthous Stomatitis, Pharyngitis, And Cervical Adenitis (Pfapa), Obstructive Sleep Apnea, Tonsillitis, Tonsil Disorder, Sleep Disordered Breathing
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 99 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2038
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Indianapolis, Indiana • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 27, 2026, 4:53 AM EDT
Completed Phase 1 Interventional

A Safety Study to Evaluate the Use and Effectiveness of a Topical Ointment to Treat Adults With Atopic Dermatitis

NCT01702181
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
OPA-15406, Tacrolimus, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Mobile, Alabama • Hot Springs, Arizona • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2014 · Synced Oct 27, 2026, 4:53 AM EDT
Completed Phase 2 Interventional Results available

CAMB/MAT2203 in Patients With Mucocutaneous Candidiasis

NCT02629419
View directory record Official record
Conditions
Candidiasis, Chronic Mucocutaneous
Interventions
Amphotericin B
Drug
Lead sponsor
Matinas BioPharma Nanotechnologies, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 27, 2026, 4:53 AM EDT
Completed Phase 2 Interventional

A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

NCT06790121
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Lunsekimig, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
23
States / cities
Encino, California • Sacramento, California • Thousand Oaks, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 27, 2026, 4:53 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Wearable Skin Sensors to Assess Nocturnal Scratch Behavior

NCT03770858
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole, Scratch sensor
Drug · Device
Lead sponsor
Northwestern University
Other
Eligibility
2 Years and older
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 13, 2023 · Synced Oct 27, 2026, 4:53 AM EDT